Although early in her career, Dr. Gloria Echeverria has already distinguished herself through impactful basic and translational cancer research combined with an ability to consistently obtain independent funding. She obtained her Ph.D. with Dr. Thomas Cooper at Baylor College of Medicine where she studied pre-mRNA splicing regulation in myotonic dystrophy type 1. During her postdoctoral studies, she conducted translational cancer research with Dr. Helen Piwnica-Worms at MD Anderson. She merged state-of-the-art in vivo models of breast cancer, quantitative biology, functional genomics, and preclinical studies. Her work elucidated intra-tumor heterogeneity in chemo resistant and metastatic breast cancers. Her findings have been published in high-impact journals and publicized with oral and poster presentations at several national conferences.

Read More

Although early in her career, Dr. Gloria Echeverria has already distinguished herself through impactful basic and translational cancer research combined with an ability to consistently obtain independent funding. She obtained her Ph.D. with Dr. Thomas Cooper at Baylor College of Medicine where she studied pre-mRNA splicing regulation in myotonic dystrophy type 1. During her postdoctoral studies, she conducted translational cancer research with Dr. Helen Piwnica-Worms at MD Anderson. She merged state-of-the-art in vivo models of breast cancer, quantitative biology, functional genomics, and preclinical studies. Her work elucidated intra-tumor heterogeneity in chemo resistant and metastatic breast cancers. Her findings have been published in high-impact journals and publicized with oral and poster presentations at several national conferences.

As a fellow, Dr. Echeverria obtained three sources of funding for her work: an American Cancer Society Postdoctoral Fellowship, a MetaVivor Early Career Investigator Grant, and a National Cancer Institute K22Career Transition Award. Her multi-disciplinary background, combined with her expertise in applying next-generation functional genomics to in vivo cancer models, will lead a productive research program at Baylor College of Medicine. Critically, her recruitment will greatly enhance studies involving cutting-edge functional genomics and will bolster our competitiveness in multi-investigator grant applications. Given her remarkable track record marked by impactful publications, steady independent funding, and numerous awards, Dr. Echeverria is an upcoming leader in the fight against breast cancer.

Read Less